← Product Code [LRG](/submissions/MI/subpart-b%E2%80%94diagnostic-devices/LRG) · K063053 # MICROSCAN MICROSTREP PLUS PANEL CEFUROXIME (0.12-8 MCG/ML) (K063053) _Dade Behring, Inc. · LRG · Oct 26, 2006 · Microbiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/LRG/K063053 ## Device Facts - **Applicant:** Dade Behring, Inc. - **Product Code:** [LRG](/submissions/MI/subpart-b%E2%80%94diagnostic-devices/LRG.md) - **Decision Date:** Oct 26, 2006 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.1640 - **Device Class:** Class 2 - **Review Panel:** Microbiology ## Intended Use To determine bacterial antimicrobial agent susceptibility ## Device Story MicroScan® MICroSTREP plus® Panel is a 96-well microdilution plate containing dehydrated antimicrobial agents. After rehydration with Mueller-Hinton broth and lysed horse blood, plates are inoculated with Streptococcus pneumoniae and incubated for 20-24 hours. The device uses optics light detection to measure bacterial growth in wells. The MicroScan® WalkAway instrument automates the reading process, replacing manual visual inspection. The system determines the Minimum Inhibitory Concentration (MIC) by identifying the lowest concentration inhibiting growth. Results assist clinicians in selecting appropriate antibiotic therapy for patients with Streptococcus pneumoniae infections. The system automatically suppresses SIR interpretation for non-pneumoniae streptococci, reporting only MIC values. ## Clinical Evidence Bench testing only. Reproducibility study (10 isolates, 3 sites, 3 days) showed >95% reproducibility for both manual and automated methods. Comparison study using 53 CDC challenge isolates of S. pneumoniae demonstrated 98.1% Essential Agreement (EA) for both manual and automated reading methods compared to reference broth dilution. No very major or major discrepancies were observed; one additional minor error occurred with the automated method. Quality control using S. pneumoniae ATCC 49619 confirmed performance consistency. ## Technological Characteristics Miniaturized broth dilution panel; 96-well format. Reagents: Mueller-Hinton broth, 2-5% lysed horse blood, 50 mM HEPES. Energy source: WalkAway instrument (electrical). Connectivity: Integrated with MicroScan WalkAway system. Sterilization: Not specified. Software: Automated optical reading of growth inhibition. ## Regulatory Identification An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases. ## Predicate Devices - MicroScan MICroSTREP plus® Panel ([K020820](/device/K020820.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K063053 OCT 26 2006 ## 510(k) Summary Information: | Device Manufacturer: | Dade Behring Inc. | |----------------------|-------------------------------------------------------------------------------------------------------------| | Contact name: | Shannon Popson, Regulatory Affairs Manager | | Phone/Fax: | 916-374-3330/916-374-3144 | | Date prepared: | September 20, 2006 | | Product Name: | Microdilution Minimum Inhibitory Concentration (MIC) Panels | | Trade Name: | MicroScan MICroSTREP plus® Panel | | Intended Use: | To determine bacterial susceptibility to Cefuroxime | | Indication for Use: | For determining antimicrobic susceptibility with aerobic streptococci
including Streptococcus pneumoniae | | Predicate device: | MicroScan MICroSTREP plus® Panel (K020820) | ## 510(k) Summary: The MicroScan MICroSTREP plus® Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of aerobic streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20-24 hours at 35℃ +/-1ºC in a non-CO2 incubator, and read according to the Package Insert. The antimicrobial susceptibility tests are miniaturizations of the broth dilution susceptibility test. Various antimicrobial agents are diluted in water, buffer or minute concentrations of broth to concentrations bridging the range of clinical interest. Panels are rehydrated with 115 ul Mueller-Hinton broth supplemented with 2-5% lysed horse blood (LHB) and buffered with 50 mM HEPES, after inoculation of the broth with a standardized suspension of the organism in saline. After incubation in a non-CO2 incubator for 20-24 hours, the minimum inhibitory concentration (MIC) for the test organism is manually read by observing the lowest antimicrobial concentration showing inhibition of growth. Additionally, the panels may be incubated in and read by a MicroScan WalkAway instrument. The proposed instrument read method for the MicroScan MICroSTREP plus® Panel demonstrated substantially equivalent performance with streptococcal isolates when compared with an expected result generated on a CLSI frozen Reference Panel, as defined in the FDA document "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA", dated February 5, 2003. This Premarket Notification (510[k]) presents data in support of reading the MICroSTREP plus® Panel with Cefuroxime on the MicroScan® WalkAway instrument. The external evaluation was conducted with stock and CDC Challenge strains. The external evaluations were designed to confirm the acceptability of the proposed instrument read method for {1}------------------------------------------------ the MICroSTREP plus® Panel by comparing its performance with Expected Results determined before the evaluation. The MICroSTREP plus® Panel demonstrated acceptable performance with an overall Essential Agreement of 98.1% for Cefuroxime instrument read results compared with the Expected Result. Instrument reproducibility testing demonstrated acceptable reproducibility and precision with Vancomcyin and the WalkAway® instrument. Quality Control testing demonstrated acceptable results for Cefuroxime. {2}------------------------------------------------ ## DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services (HHS) in the United States. The logo features the department's name in a circular arrangement around a stylized emblem. The emblem consists of an abstract representation of an eagle or bird-like figure, with three curved lines forming its body and wings. Public Health Service Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Ms. Shannon Popson Regulatory Affairs Manager Dade Behring, Inc. 1584 Enterprise Boulevard West Sacramento, CA 95691-9972 Re: k063053 > Trade/Device Name: MicroScan MICroSTREP plus® Panel Cefuroxime (0.12 - 8 mcg/ml) Regulation Number: 21 CFR § 866.1640 Regulation Name: Antimicrobial susceptibility test powder Regulatory Class: II Product Code: LRG, LTT Dated: September 20, 2006 Received: October 4, 2006 Dear Ms. Poposon: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. OCT 26 2006 If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). {3}------------------------------------------------ This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html. Sincerely yours, Sally, anton Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## Indication for Use Statement 163053 MicroScan MICroSTREP plus® Panel Cefuroxime (0.12 - 8 mcg/ml) (To be assigned by FDA 510(k) No.: Device Name: Intended Use To determine bacterial antimicrobial agent susceptibility Indications for Use: The MicroScan MICroSTREP plus® Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of aerobic streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20 - 24 hours at 35°C +/- 1°C in a non-CO2 incubator, and read visually according to the Package Insert. Additionally, the panels may be incubated in and read by a MicroScan® WalkAway instrument. This particular submission is for the addition of instrument read capability of the antimicrobial Cefuroxime, at concentrations of 0.12 to 8 mcg/ml on the MicroScan MICroSTREP plus® Panel. The organisms which may be used for Cefuroxime susceptibility testing in this panel are: Streptococcus pneumoniae Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Lunddite Pauly **Division Sign-Off** Office of In Vitro Diagnostic Device Page 1 of 1 Evaluation and Safety 06 305 viii --- **Source:** [https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/LRG/K063053](https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/LRG/K063053) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com